Bouma BN, Griffin JH (1977) Human blood coagulation factor XI. Purification, properties, and mechanism of activation by activated factor XII. J Biol Chem 252:6432–6437

Ho DH, Badellino K, Baglia FA, Sun M-F, Zhao M-M, Gailani D, Walsh PN (2000) The role of high molecular weight kininogen and prothrombin as cofactors in the binding of factor XI A3 domain to the platelet surface. J Biol Chem 275:25139–25145

Article  CAS  PubMed  Google Scholar 

Sun Y, Gailani D (1996) Identification of a factor IX binding site on the third apple domain of activated factor XI. J Biol Chem 271:29023–29028

Article  CAS  PubMed  Google Scholar 

Baglia FA, Walsh PN (2007) Prothrombin is a cofactor for the binding of factor XI to the platelet surface and for platelet-mediated factor-XI activation by thrombin. Biochemistry 46:12886–12887

Article  CAS  Google Scholar 

Papagrigoriou E, McEwan PA, Walsh PN, Emsley J (2006) Crystal structure of the factor XI zymogen reveals a pathway for transactivation. Nat Struct Mol Biol 13:557–558

Article  CAS  PubMed  Google Scholar 

McMullen BA, Fujikawa K, Davie EW (1991) Location of the disulfide bonds in human coagulation factor XI: the presence of tandem apple domains. Biochemistry 30:2056–2060. https://doi.org/10.1021/bi00222a008

Article  CAS  PubMed  Google Scholar 

Wang X, Smith P, Hsu MY, Gailani D, Schumacher W, Ogletree M, Seiffert D (2006) Effects of factor XI deficiency on ferric chloride-induced vena cava thrombosis in mice. J Thromb Haemost 4:1982–1988

Article  CAS  PubMed  Google Scholar 

Wu W, Sinha D, Shikov S, Yip CK, Walz T, Billings PC, Lear JD, Walsh PN (2008) Factor XI homodimer structure is essential for normal proteolytic activation by factor XIIa, thrombin, and factor XIa. J Biol Chem 283:18655–18664

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hsu C, Hutt E, Bloomfield DM, Gailani D, Weitz JI (2021) Factor XI inhibition to uncouple thrombosis from hemostasis: JACC review topic of the week. J Am Coll Cardiol 78:625–631

Article  CAS  PubMed  PubMed Central  Google Scholar 

Woodruff RS, Sullenger B, Becker RC (2011) The many faces of the contact pathway and their role in thrombosis. J Thromb Thrombolysis 32:9–20. https://doi.org/10.1007/s11239-011-0578-5

Article  PubMed  Google Scholar 

Greco A, Laudani C, Spagnolo M, Agnello F, Faro DC, Finocchiaro S, Legnazzi M, Mauro MS, Mazzone PM, Occhipinti G (2023) Pharmacology and clinical development of factor XI inhibitors. Circulation 147:897–913

Article  CAS  PubMed  Google Scholar 

Yau JW, Liao P, Fredenburgh JC, Stafford AR, Revenko AS, Monia BP, Weitz JI (2014) Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. Blood 123:2102–2107

Article  CAS  PubMed  Google Scholar 

Meijers JC, Tekelenburg WL, Bouma BN, Bertina RM, Rosendaal FR (2000) High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 342:696–701

Article  CAS  PubMed  Google Scholar 

Salomon O, Steinberg DM, Zucker M, Varon D, Zivelin A, Seligsohn U (2011) Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis. Thromb Haemost 105:269–273

Article  CAS  PubMed  Google Scholar 

Schumacher WA, Luettgen JM, Quan ML, Seiffert DA (2010) Inhibition of factor XIa as a new approach to anticoagulation. Arterioscler Thromb Vasc Biol 30:388–392

Article  CAS  PubMed  Google Scholar 

Kleinschnitz C, Stoll G, Bendszus M, Schuh K, Pauer H-U, Burfeind P, Renné C, Gailani D, Nieswandt B, Renné T (2006) Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 203:513–518

Article  CAS  PubMed  PubMed Central  Google Scholar 

Takahashi M, Yamashita A, Moriguchi-Goto S, Sugita C, Matsumoto T, Matsuda S, Sato Y, Kitazawa T, Hattori K, Shima M (2010) Inhibition of factor XI reduces thrombus formation in rabbit jugular vein under endothelial denudation and/or blood stasis. Thromb Res 125:464–470

Article  CAS  PubMed  Google Scholar 

Perera V, Wang Z, Luettgen J, Li D, DeSouza M, Cerra M, Seiffert D (2022) First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor. Clin Transl Sci 15:330–342

Article  CAS  PubMed  Google Scholar 

Thomas D, Kanefendt F, Schwers S, Unger S, Yassen A, Boxnick S (2021) First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa. J Thromb Haemost 19:2407–2416

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kubitza D, Heckmann M, Distler J, Koechel A, Schwers S, Kanefendt F (2022) Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: a randomized phase 1 multiple-dose study. Br J Clin Pharmacol 88:3447–3462

Article  CAS  PubMed  Google Scholar 

Büller HR, Gailani D, Weitz JI (2015) Factor XI antisense oligonucleotide for venous thrombosis. N Engl J Med 372:1672–1672

Article  PubMed  Google Scholar 

Chan NC, Weitz JI (2019) AB023, a novel antibody that binds factor XI and blocks its activation by factor XIIa. Arterioscler Thromb Vasc Biol 39:533–535

Lorentz CU, Verbout NG, Wallisch M, Hagen MW, Shatzel JJ, Olson SR, Puy C, Hinds MT, McCarty OJ, Gailani D (2019) Contact activation inhibitor and factor XI antibody, AB023, produces safe, dose-dependent anticoagulation in a phase 1 first-in-human trial. Arterioscler Thromb Vasc Biol 39:799–809

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nowotny B, Thomas D, Schwers S, Wiegmann S, Prange W, Yassen A, Boxnick S (2022) First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men. J Thromb Haemost 20:1684–1695. https://doi.org/10.1111/jth.15744

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weitz JI, Chan NC (2020) Novel antithrombotic strategies for treatment of venous thromboembolism. Blood 135:351–359

Article  PubMed  Google Scholar 

Yi BA, Freedholm D, Widener N, Wang X, Simard E, Cullen C, Al-Saady NM, Lepor NE, Coulter S, Lovern M (2022) Pharmacokinetics and pharmacodynamics of abelacimab (MAA868), a novel dual inhibitor of factor XI and factor XIa. J Thromb Haemost 20:307–315

Article  CAS  PubMed  Google Scholar 

Walsh M, Bethune C, Smyth A, Tyrwhitt J, Jung SW, Rosie ZY, Wang Y, Geary RS, Weitz J, Bhanot S (2022) Phase 2 study of the factor XI antisense inhibitor IONIS-FXIRx in patients with ESRD. Kidney Int Rep 7:200–209

Article  PubMed  Google Scholar 

Verhamme P, Yi BA, Segers A, Salter J, Bloomfield D, Büller HR, Raskob GE, Weitz JI (2021) Abelacimab for prevention of venous thromboembolism. N Engl J Med 385:609–617

Article  CAS  PubMed  Google Scholar 

Weitz JI, Eikelboom JW (2022) What is the future of factor XI inhibitors? Circulation 146:1899–1902

Article  PubMed  Google Scholar 

Piccini JP, Caso V, Connolly SJ, Fox KA, Oldgren J, Jones WS, Gorog DA, Durdil V, Viethen T, Neumann C (2022) Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. Lancet 399:1383–1390

Article  CAS  PubMed  Google Scholar 

Shoamanesh A, Mundl H, Smith EE, Masjuan J, Milanov I, Hirano T, Agafina A, Campbell B, Caso V, Mas J-L (2022) Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet 400:997–1007

Article  CAS  PubMed  Google Scholar 

Rao SV, Kirsch B, Bhatt DL, Budaj A, Coppolecchia R, Eikelboom J, James SK, Jones WS, Merkely B, Keller L (2022) A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction. Circulation 146:1196–1206

Article  CAS  PubMed  Google Scholar 

Sharma M, Molina CA, Toyoda K, Bereczki D, Kasner SE, Lutsep HL, Tsivgoulis G, Ntaios G, Czlonkowska A, Shuaib A (2022) Rationale and design of the AXIOMATIC-SSP phase II trial: antithrombotic treatment with factor XIa inhibition to optimize management of acute thromboembolic events for secondary stroke prevention. J Stroke Cerebrovasc Dis 31:106742

Article  PubMed  PubMed Central  Google Scholar 

Zhang H, Löwenberg EC, Crosby JR, MacLeod AR, Zhao C, Gao D, Black C, Revenko AS, Meijers JC, Stroes ES (2010) Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood 116:4684–4692

Article  CAS  PubMed  Google Scholar 

Büller HR, Bethune C, Bhanot S, Gailani D, Monia BP, Raskob GE, Segers A, Verhamme P, Weitz JI (2015) Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med 372:232–240

Article  PubMed  Google Scholar 

Willmann S, Marostica E, Snelder N, Solms A, Jensen M, Lobmeyer M, Lensing AW, Bethune C, Morgan E, Yu RZ (2021) PK/PD modeling of FXI antisense oligonucleotides to bridge the dose‐FXI activity relation from healthy volunteers to end‐stage renal disease patients. CPT: Pharmacometrics Syst Pharmacol 10:890–901